| Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping DR Borger, KK Tanabe, KC Fan, HU Lopez, VR Fantin, KS Straley, ... The oncologist 17 (1), 72-79, 2012 | 835 | 2012 |
| RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer MJ Niederst, LV Sequist, JT Poirier, CH Mermel, EL Lockerman, ... Nature communications 6 (1), 6377, 2015 | 602 | 2015 |
| TBCRC009: a multicenter phase II clinical trial of platinum monotherapy with biomarker assessment in metastatic triple-negative breast cancer SJ Isakoff, EL Mayer, L He, TA Traina, LA Carey, KJ Krag, HS Rugo, ... Journal of clinical oncology 33 (17), 1902-1909, 2015 | 477 | 2015 |
| Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice LV Sequist, RS Heist, AT Shaw, P Fidias, R Rosovsky, JS Temel, ... Annals of Oncology 22 (12), 2616-2624, 2011 | 475 | 2011 |
| Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine D Dias‐Santagata, S Akhavanfard, SS David, K Vernovsky, G Kuhlmann, ... EMBO molecular medicine 2 (5), 146-158, 2010 | 413 | 2010 |
| Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non–small-cell lung cancer LV Sequist, S Gettinger, NN Senzer, RG Martins, PA Jänne, R Lilenbaum, ... Journal of clinical oncology 28 (33), 4953-4960, 2010 | 387 | 2010 |
| BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications D Dias-Santagata, Q Lam, K Vernovsky, N Vena, JK Lennerz, DR Borger, ... PloS one 6 (3), e17948, 2011 | 371 | 2011 |
| Phase 1/2 study of everolimus in advanced hepatocellular carcinoma AX Zhu, TA Abrams, R Miksad, LS Blaszkowsky, JA Meyerhardt, H Zheng, ... Cancer 117 (22), 5094-5102, 2011 | 245 | 2011 |
| A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non–small-cell lung cancer Z Su, D Dias-Santagata, MK Duke, K Hutchinson, YL Lin, DR Borger, ... The Journal of Molecular Diagnostics 13 (1), 74-84, 2011 | 234 | 2011 |
| Genomic characterization of human brain metastases identifies drivers of metastatic lung adenocarcinoma DJH Shih, N Nayyar, I Bihun, I Dagogo-Jack, CM Gill, E Aquilanti, ... Nature genetics 52 (4), 371-377, 2020 | 224 | 2020 |
| Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas H Wakimoto, S Tanaka, WT Curry, F Loebel, D Zhao, K Tateishi, J Chen, ... Clinical cancer research 20 (11), 2898-2909, 2014 | 207 | 2014 |
| Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer EL Kwak, LG Ahronian, G Siravegna, B Mussolin, DR Borger, JT Godfrey, ... Cancer discovery 5 (12), 1271-1281, 2015 | 177 | 2015 |
| Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping RS Heist, LV Sequist, D Borger, JF Gainor, RS Arellano, LP Le, ... Journal of Thoracic Oncology 11 (8), 1242-1245, 2016 | 162 | 2016 |
| Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma DR Borger, L Goyal, T Yau, RT Poon, M Ancukiewicz, V Deshpande, ... Clinical Cancer Research 20 (7), 1884-1890, 2014 | 149 | 2014 |
| Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying therapeutic targets AX Zhu, DR Borger, Y Kim, D Cosgrove, A Ejaz, S Alexandrescu, ... Annals of surgical oncology 21, 3827-3834, 2014 | 148 | 2014 |
| Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma L Goyal, A Govindan, RA Sheth, V Nardi, LS Blaszkowsky, JE Faris, ... The oncologist 20 (9), 1019-1027, 2015 | 145 | 2015 |
| EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas RJH Ryan, M Nitta, D Borger, LR Zukerberg, JA Ferry, NL Harris, ... PloS one 6 (12), e28585, 2011 | 144 | 2011 |
| Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response AT Fathi, H Sadrzadeh, DR Borger, KK Ballen, PC Amrein, EC Attar, ... Blood, The Journal of the American Society of Hematology 120 (23), 4649-4652, 2012 | 136 | 2012 |
| Activation of PI3K signaling in Merkel cell carcinoma V Nardi, Y Song, JA Santamaria-Barria, AK Cosper, Q Lam, AC Faber, ... Clinical Cancer Research 18 (5), 1227-1236, 2012 | 129 | 2012 |
| Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment V Nardi, PM Sadow, D Juric, D Zhao, AK Cosper, K Bergethon, ... Clinical cancer research 19 (2), 480-490, 2013 | 117 | 2013 |
